Supriya Lifescience is eyeing up to Rs 1,600 crore revenue from its Lote MIDC in Ratnagiri and Ambernath facilities in the next three years. The company's Patalganga facility will take 2.5-3 years to become operational.
The company had a capex of Rs 160 crore for setting up its Ambernath facility, and Rs 350 crore for the Patalganga unit, which will be spent in a phased manner.
Supriya Lifescience is one of the key Indian manufacturers and suppliers of active pharmaceuticals ingredients (APIs), with a focus on research and development.
